T0	Participants 88 163	patients with non-small cell lung cancer not suitable for curative therapy:
T1	Participants 743 896	Patients were eligible if they had stage I-IIIB NSCLC, unsuitable for curative therapy, or stage IV with a PET-detected extracranial solitary metastasis.
T2	Participants 1290 1327	Eighty-four patients were randomized.